These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28445830)

  • 21. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
    Xu X; Zhang X; Liu Y; Yang L; Huang S; Lu L; Wang S; Guo Q; Zhao L
    Oncotarget; 2016 Apr; 7(17):24436-54. PubMed ID: 27027438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.
    Tibullo D; Barbagallo I; Giallongo C; La Cava P; Parrinello N; Vanella L; Stagno F; Palumbo GA; Li Volti G; Di Raimondo F
    Curr Pharm Des; 2013; 19(15):2765-70. PubMed ID: 23092325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
    Sorrenti V; Pittalà V; Romeo G; Amata E; Dichiara M; Marrazzo A; Turnaturi R; Prezzavento O; Barbagallo I; Vanella L; Rescifina A; Floresta G; Tibullo D; Di Raimondo F; Intagliata S; Salerno L
    Eur J Med Chem; 2018 Oct; 158():937-950. PubMed ID: 30261468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting histone deacetylase 1 (HDAC1) in the bone marrow stromal cells revers imatinib resistance by modulating IL-6 in Ph + acute lymphoblastic leukemia.
    Wei D; Liang X; Huang M; Wang C; Ye Z; Zhang T; Zhang J
    Ann Hematol; 2024 Aug; 103(8):3015-3027. PubMed ID: 38847852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells.
    Wu J; Wei B; Wang Q; Ding Y; Deng Z; Lu X; Li Y
    Cell Biochem Biophys; 2016 Jun; 74(2):277-83. PubMed ID: 26912059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation.
    Lu T; Wei D; Yu K; Ma D; Xiong J; Fang Q; Wang J
    Ann N Y Acad Sci; 2020 May; 1467(1):77-93. PubMed ID: 31930541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes multiple myeloma resistance through the JAK2/STAT3 pathway.
    Huang J; Huang LQ; He HS; Yan J; Huang C; Wang R; Guan Y; Huang DP
    Life Sci; 2020 Sep; 257():118088. PubMed ID: 32663573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
    Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
    Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
    Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
    Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
    Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
    Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extracellular vesicle-mediated regulation of imatinib resistance in chronic myeloid leukemia via the miR-629-5p/SENP2/PI3K/AKT/mTOR axis.
    Jiang Y; Xiao S; Huang S; Zhao X; Ding S; Huang Q; Xiao W; Li Z; Zhu H
    Hematology; 2024 Dec; 29(1):2379597. PubMed ID: 39056503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.
    Zhang X; Tu H; Yang Y; Wan Q; Fang L; Wu Q; Li J
    Int J Hematol; 2016 Sep; 104(3):358-67. PubMed ID: 27272942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The anti-tumoral effect of PI3K inhibitor and MEK inhibitor combined with STI571 on chronic myeloid leukemia cells in a bone marrow stromal cell co-culture system].
    Jin L; Kato A; Tabe Y
    Rinsho Ketsueki; 2006 Oct; 47(10):1364-71. PubMed ID: 17094575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
    PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis.
    Han Y; Ma Z
    Anticancer Drugs; 2021 Apr; 32(4):427-436. PubMed ID: 33587348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
    Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D
    Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
    Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
    Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
    Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
    BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.